Your AI-Trained Oncology Knowledge Connection!
The novel irreversible EGFR exon 20 insertion inhibitor sunvozertinib demonstrated significant clinical activity and similar safety to prior reports in Chinese patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on prior platinum-based chemotherapy, according to results from the phase 2 WO-KONH6 study.
The addition of pembrolizumab to pemetrexed and platinum-based chemotherapy resulted in a numerical, but not statistically significant, improvement in progression-free survival or overall survival vs chemotherapy plus placebo in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer.
Katherine B. Peters, MD, PhD, discusses findings from the phase 3 INDIGO trial of vorasidenib in patients with recurrent or residual grade 2 glioma harboring an IDH1 or IDH2 mutation and how these results support the addition of vorasidenib to the treatment armamentarium.
Treatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the RAMP 201 trial.
Prithviraj Bose, MD, discusses key data on the ability of pacritinib to reduce splenomegaly and disease symptoms in patients with myelofibrosis across the cytopenic spectrum.
Thierry Andre, MD, discusses negative overall survival results and updated safety data from the phase 3 SOLSTICE trial in metastatic colorectal cancer.
The use of maintenance niraparib enhanced antitumor activity and led to a clinically meaningful increase in progression-free survival vs placebo for patients with newly diagnosed advanced ovarian cancer who displayed measurable residual disease after first-line platinum-based chemotherapy, according to findings from a post hoc subgroup analysis of the phase 3 PRIME study.
Second-line maintenance therapy with niraparib improved overall survival vs active surveillance in patients with recurrent BRCA wild-type ovarian cancer.
The addition of the soluble LAG-3 protein eftilagimod alpha to pembrolizumab produced responses and was well tolerated in patients with metastatic head and neck squamous cell carcinoma.
Extended lymphadenectomy at the time of radical cystectomy did not produce a significant improvement in disease-free survival (DFS) or overall survival (OS) vs standard lymphadenectomy for patients with muscle-invasive bladder cancer.
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.
The addition of sintilimab to chemoradiotherapy demonstrated a significant reduction in the risk of disease recurrence or death, distant metastasis and locoregional recurrence compared with chemoradiotherapy alone as frontline therapy in patients with locally advanced nasopharyngeal carcinoma, according to findings from the phase 3 CONTINUUM trial.
Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in patient with pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.
The combination of pembrolizumab plus axitinib continued to improve overall survival, progression-free survival, and overall response rate over sunitinib monotherapy in patients with treatment-naïve clear cell renal cell carcinoma.
Jun Ma, MD, discusses findings from the phase 3 CONTINUUM trial of sintilimab in combination with induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
Hussein A. Tawbi, MD, PhD, discusses the 2-year findings from the phase 2/3 RELATIVITY-047 trial of nivolumab plus relatlimab in treatment-naïve patients with metastatic or unresectable melanoma.
The addition of atezolizumab to cabozantinib did not improve progression-free survival or overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma who previously received treatment with an immune checkpoint inhibitor, missing the primary end points of the phase 3 CONTACT-03 trial.
The SEZ6-targeted antibody-drug conjugate ABBV-011, when administered at 1 mg/kg every 3 weeks, was found to be well tolerated and to demonstrate early efficacy in patients with relapsed or refractory small cell lung cancer.
Ciltacabtagene autoleucel significantly improved progression-free survival over standard-of-care pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.
Treatment with fruquintinib plus best supportive care led to improved overall survival and progression-free survival vs placebo plus best supportive care in patients with refractory metastatic colorectal cancer, irrespective of number of prior lines of therapy or type of prior treatment.
Longer follow-up data from the phase 2 ELAINE-2 study demonstrated that treatment with lasofoxifene and abemaciclib resulted in clinically meaningful antitumor activity as well as continued tolerability with no new safety signals for patients with estrogen receptor-positive HER2-negative ESR1-mutated breast cancer who previously received CDK4/6 inhibitors.
Treatment with doxorubicin plus zalifrelimab and balstilimab produced a favorable 6-month progression-free survival rate in patients with difficult-to-treat soft tissue sarcoma subtypes unlikely to respond to doxorubicin or immune checkpoint inhibitor monotherapy.
The combination of trifluridine/tipiracil and bevacizumab did not demonstrate a significant overall survival benefit vs capecitabine plus bevacizumab in patients with unresectable, metastatic colorectal cancer ineligible for intensive chemotherapy.
Darolutamide was well tolerated and generated clinically meaningful activity across secondary end points in the treatment of patients with androgen receptor–positive salivary gland cancer.
Lenvatinib plus pembrolizumab (Keytruda) showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma.
Patritumab deruxtecan displayed manageable safety and produced responses in heavily pretreated patients with estrogen receptor–positive or triple-negative metastatic breast cancer with varying levels of HER3 expression, according to data from a phase 2 study presented at the 2023 ASCO Annual Meeting.
The combination of enfortumab vedotin-ejfv and pembrolizumab generated rapid and durable responses and demonstrated a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.
The addition of nivolumab and ipilimumab to cabozantinib led to an improvement in disease control rate and progression-free survival vs cabozantinib alone in patients with metastatic soft tissue sarcoma.
The protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 demonstrated preliminary antitumor activity and acceptable safety for patients with recurrent high-grade glioma and advanced or metastatic uveal melanoma, according to data from the dose-expansion portion of a phase 1 trial presented at the 2023 ASCO Annual Meeting.
